Ligand Pharma (LGND) Tops Q1 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ligand Reports First Quarter 2016 Financial Results
May 4, 2016 6:01 AM EDTManagement to discuss the quarter during an investment conference presentation beginning at 1:30 p.m. Eastern time today
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2016, and provided an operating forecast and program updates.
Financial highlights for the first quarter of 2016 include:
First quarter total revenues were $29.6 million, including royalty revenues of $14.4 million. First quarter adjusted EPS was $0.97 and GAAP EPS was $0.30.A description of adjusted calculations and reconciliation... More
